GAITHERSBURG, MD - January 19, 2021 – NexImmune, a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response that mimics natural biology, today announced the appointment of Grant Verstandig to its Board of Directors.
“We are delighted to welcome Grant to the NexImmune Board,” said Sol Barer, PhD, Chairman of NexImmune’s Board of Directors. “Grant is a recognized innovator and leader in the evolving fields of digital health and artificial intelligence (AI). We believe that better understanding the intersections of biology, big data and artificial intelligence is a clear trend in our industry and will greatly help the Company design, implement and collect outcomes on clinical trials that may truly transform the way we develop novel therapeutics. We look forward to working with him as we continue the development of our product candidates and technology platform.”